Skip to Content
CancersCancers
  • Article
  • Open Access

2 September 2023

15 Pages

Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis

,
,
,
,
,
,
,
,
and
1
Unità Linfomi, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
2
Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
3
Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, 40126 Bologna, Italy
4
Novartis Farma S.p.A., 20154 Milan, Italy
This article belongs to the Special Issue Advances in Follicular Lymphoma

Simple Summary

This study analysed the state-of-the-art of follicular lymphoma in Italy in a real-world clinical setting, giving special attention to patients who underwent three or more treatment lines. The overall message emerging from the analysis is that progression through several lines during the management of patients diagnosed with follicular lymphoma results in more complex clinical status, and more relevant financial implications for sustainability by the National Health Service. Thus, at the forefront of efforts of current research to broaden the landscape of therapeutic strategies to manage this disease, the mortality rates are still high, revealing an unmet clinical need for patients with multiple lines.

Abstract

This real-world analysis investigated patients with follicular lymphoma in Italy receiving three or more treatment lines (≥3L), focusing on therapeutic pathways with their rebounds on healthcare resource consumptions and costs. Data were retrieved from administrative databases from healthcare entities covering about 13.3 million residents. Adults diagnosed with follicular lymphoma were identified between January 2015 and June 2020, and among them 2434 patients with ≥3L of treatment during the data availability interval (January 2009 to June 2021) were included. Of them, 1318 were in 3L, 494 in 4L and 622 in ≥5L. A relevant proportion of patients (12–32%) switched to a later line within the same calendar year. At 3-year follow-up (median), 34% patients died. Total mean annual expenses were euro 14,508 in the year preceding inclusion and rose to euro 21,081 at 1-year follow-up (on average euro 22,230/patient/year for the whole follow-up), with hospitalization and drug expenses as weightiest cost items. In conclusion, the clinical and economic burden of follicular lymphoma increases along with later treatment lines. The high mortality rates indicate that further efforts are needed to optimize disease management.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.